Опыт длительного применения омализумаба у детей с тяжелой бронхиальной астмой

Л. В. Соколова, С Э Цыпленкова, Ludmila Sorokina et al. · Земский врач · 2011

Inflammation is one of the main pathological factors of asthma. Omalizumab is an antibody to IgE, so it belongs to the antiinflammatory drugs of the new generation. The article describes the experience of using the drug for the treatment of children with asthma in the Moscow SRI for Pediatrics and Pediatric Surgery

Cited by 0 works.

Authors